Neurocrine Biosciences, Inc. (NBIX) Cash Flow Statement

Operating cash flow was $395.2M against net income of $206.5M in 2026Q3, and the ratio has exceeded 1.0x in six of the last ten quarters. Several quarters, including 2025Q1 at 8.20x, show ratios that are inflated by a very low net income base rather than by unusually strong cash generation, so the ratio should be read with caution. Investors should monitor whether conversion remains above 1.0x as earnings normalize.

The wide margin band reflects quarterly swings in working capital and collections rather than a steady structural trend. Capital expenditure remains small at roughly 0.3% to 2.0% of revenue, so FCF movements are driven almost entirely by operating cash flow variability. The trajectory suggests improving underlying profitability, but the quarter-to-quarter dispersion warrants further investigation before extrapolating recent strength.

Large working capital inflows in several quarters, including $119.2M in 2025Q4 and $94.3M in 2024Q4, suggest that collections timing or receivable and payable settlement is a significant driver of reported operating cash flow. These reversals imply that quarterly OCF is not a clean proxy for steady-state cash earnings. Investors should monitor whether the inflows reflect durable efficiency or timing effects that may reverse.

The absence of dividends and the episodic, sizable nature of repurchases suggest management prioritizes flexibility over a recurring payout. Buyback timing appears to track periods of strong operating cash flow, which may indicate deployment is opportunistic rather than programmatic. Investors should monitor whether repurchases continue to be funded from operating cash flow or from balance sheet reserves.